Form 4: Sutro Biopharma CEO William Newell Reports Stock Transactions
SEC Form 4 Filing
William Newell, CEO of Sutro Biopharma, reports the vesting and tax withholding of restricted stock units.
Summary
- On March 5, 2025, William J. Newell, CEO of Sutro Biopharma, engaged in transactions involving the company's common stock and restricted stock units (RSUs).
- 18,750 shares were acquired through the vesting of RSUs.
- 6,708 shares were withheld by the issuer to cover income tax obligations related to the RSU settlement.
- The price per share for the tax withholding was $1.36.
- Following these transactions, Newell directly owns 292,531 shares and indirectly owns 116,525 shares through the William J. Newell Family Trust DTD 03/15/2019.
Sentiment
Score: 7
Explanation: The document reflects routine executive compensation activity, which is neither particularly positive nor negative. It's a neutral disclosure required by regulations.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect standard executive compensation practices.
Key Dates
| Date | Description |
|---|---|
| 03/15/2019 | Date of William J. Newell Family Trust |
| 03/05/2022 | Initial vesting date of RSUs (1/4th of total shares) |
| 03/05/2025 | Date of reported transactions: RSU vesting and tax withholding |
| 03/07/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.